- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06855238
Clinical Validation of an Artificial Intelligence Tool to Predict Inversion Time (THAITI-V)
Introduction: Inversion-recovery (IR) magnetic resonance (MR) sequences are commonly used to perform late-gadolinium enhancement (LGE) imaging during cardiac magnetic resonance (CMR) scans. Inversion Time (TI), i.e. the time between the 180° inverting pulse and the 90°-pulse, must be manually input to obtain optimal myocardium nulling. Determinants of this value are patient's, sequence, and contrast characteristics, and the time after contrast injection. The identification of the correct TI is pivotal to quality images. The determination of TI is mostly based on experience, and it can be challenging in some diseases and for less experienced operators.
Aim of this study is to test in a clinical setting an Artificial Intelligence (AI) tool, which we developed to automatically predict TI in CMR post-contrast IR LGE sequences, named "THAITI".
THAITI performance will be evaluated in terms of 1) quality of images obtained using the AI-predicted TI with a 4-point Likert scale; 2) quality of images obtained using the AI-predicted TI in terms of Contrast-Enhancement ratio, i.e. the signal intensity of enhanced/remote myocardium in CMR-LGE images; 3) numbers of images that need to be reacquired; 4) average time duration of CMR-LGE imaging.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Milan, Italy
- Istituto Auxologico Italiano IRCCS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients in whom CMR-LGE is performed for a clinical reason
- Mixed cardiac conditions (including cardiomyopathies, ischemic heart disease, normal scans, focal and diffuse myocardial pathological processes)
- Both sexes
- Any age
- Availability of serum creatinine, measured within one month prior to CMR
- Provision of the written informed consent
Exclusion Criteria:
- Non-contrast CMR
- First-pass perfusion stress-CMR
- Absolute contraindication to CMR
- Inadequate overall image quality
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Operator-set TI (control group)
During the cardiovascular magnetic resonance scan, the TI is set by an experienced human operator as per standard clinical practice
|
|
|
Experimental: THAITI-set TI
During the cardiovascular magnetic resonance scan, the TI is set by the experimental software
|
THAITI is an AI-based software which predicts on the fly personalised TI for late gadolinium enhancement imaging during cardiovascular magnetic resonance scans. The clinical investigators will be provided by the computer scientists investigators with a software, based on the developed AI model. During the CMR in the experimental group, investigators will input patients' data on the software (e.g. age, sex, dose of contrast…). The software will provide a TI value to be input in the MRI scanner. TI will be set accordingly to the AI prediction. A LGE series of 3 long axis (4-, 2- and 3-chambers view) and a short-axis stack will be acquired. For all the patients, a doctor expert in CMR will be at the scanner and quality check the images in real time. Every image where the myocardium is not optimally nulled will be repeated with a TI set by the CMR doctor. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Images quality proportion
Time Frame: At examination
|
Proportion of images with optimal/good quality
|
At examination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
contrast-enhancement ratio
Time Frame: At examination
|
Contrast-Enhancement ratio (CER)
|
At examination
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09C335
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
Hull University Teaching Hospitals NHS TrustNot yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)United Kingdom
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and other collaboratorsRecruitingCardiovascular Risk | Genetic Cardiovascular RiskItaly
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiovascular Diseases (CVD)United States
Clinical Trials on THAITI software
-
Hams Hamed AbdelrahmanCompletedAccuracy of Digital Dental ModelEgypt
-
University of California, San FranciscoRecruitingMild Cognitive Impairment | Long-Term Memory DeclineUnited States
-
Cairo UniversityRecruitingSegmentation; BoneEgypt
-
The Methodist Hospital Research InstituteNational Institute on Aging (NIA)CompletedVirtual RealityUnited States
-
Wuhan Union Hospital, ChinaCompleted
-
Prof. Arseny Sokolov, MD, PhDNot yet recruiting
-
Methinks Software SLSantiago Ortega- global PINot yet recruitingBrain Ischemia | Stroke, Ischemic | Stroke, Acute | Stroke Hemorrhagic
-
Madigan Army Medical CenterTelemedicine & Advanced Technology Research Center; Analytics4Medicine, LLCTerminated
-
ProlaioCompletedHeart Failure | Cardiomyopathy, Hypertrophic | Left Ventricular HypertrophyUnited States
-
Medical Decision Logic, Inc.Unknown